Table 3.
IFNγ T cell responses.
| Antigen | Gardasil vaccinated CD4/CD154/IFNγ positive T cells Median frequency (IQR) | Number of subjects | p-value | Cervarix vaccinated CD4/CD154/IFNγ positive T cells Median frequency (IQR) | Number of subjects | p-value |
|---|---|---|---|---|---|---|
| HPV6 L1 | ||||||
| Baseline | 0.000 (0.000–0.010) | 14 | 0.000 (0.000–0.010) | 13 | ||
| 7 months | 0.020 (0.015–0.065) | 13 | 0.006 | 0.020 (0.000–0.050) | 15 | 0.017 |
| 12 months | 0.030 (0.020–0.060) | 15 | 0.001 | 0.010 (0.000–0.060) | 15 | 0.18 |
| HPV11 L1 | ||||||
| Baseline | 0.000 (0.000–0.010) | 14 | 0.000 (0.000–0.005) | 13 | ||
| 7 months | 0.030 (0.010–0.050) | 15 | 0.015 | 0.010 (0.000–0.030) | 15 | 0.024 |
| 12 months | 0.020 (0.010–0.030) | 15 | 0.022 | 0.010 (0.000–0.020) | 14 | 0.023 |
| HPV16 L1 | ||||||
| Baseline | 0.000 (0.000–0.010) | 14 | 0.000 (0.000–0.000) | 15 | ||
| 7 months | 0.030 (0.010–0.050) | 15 | 0.011 | 0.015 (0.000–0.040) | 14 | 0.007 |
| 12 months | 0.030 (0.010–0.050) | 15 | 0.047 | 0.010 (0.000–0.030) | 15 | 0.007 |
| HPV18 L1 | ||||||
| Baseline | 0.000 (0.000–0.000) | 14 | 0.000 (0.000–0.020) | 14 | ||
| 7 months | 0.010 (0.000–0.020) | 15 | 0.022 | 0.010 (0.000–0.030) | 15 | 0.039 |
| 12 months | 0.010 (0.000–0.020) | 15 | 0.014 | 0.000 (0.000–0.020) | 15 | 0.719 |
| HPV31 L1 | ||||||
| Baseline | 0.000 (0.000–0.003) | 14 | 0.000 (0.000–0.010) | 15 | ||
| 7 months | 0.010 (0.000–0.040) | 15 | 0.016 | 0.010 (0.000–0.040) | 15 | 0.011 |
| 12 months | 0.010 (0.000–0.030) | 15 | 0.014 | 0.020 (0.010–0.040) | 15 | 0.009 |
| HPV45 L1 | ||||||
| Baseline | 0.000 (0.000–0.010) | 14 | 0.000 (0.000–0.010) | 14 | ||
| 7 months | 0.010 (0.000–0.020) | 13 | 0.19 | 0.010 (0.000–0.010) | 14 | 0.558 |
| 12 months | 0.010 (0.010–0.030) | 15 | 0.015 | 0.010 (0.000–0.015) | 13 | 0.715 |